A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis

W. Hader; P. Duquette; A. Auty Winnipeg; S. Hashimoto; J. Noseworthy; G. Sawa; D. Brunet; R. Nelson; T. Gray; G. Klein; G. Francis; Y. Lapierre; B. Weinshenker; W. Barkas; S. Philips; M. Girard; T. J. Murray

doi:10.1017/S0317167100026603

A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis

W. Hader, P. Duquette, A. Auty Winnipeg, S. Hashimoto, J. Noseworthy, G. Sawa, D. Brunet, R. Nelson, T. Gray, G. Klein, G. Francis, Y. Lapierre, B. Weinshenker, W. Barkas, S. Philips, M. Girard, T. J. Murray

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

142 Citas (Scopus)

Resumen

One hundred and fifteen patients with definite multiple sclerosis (M.S.) and chronic persistent fatigue were studied. This ten-week cross-over study consisted of a 2-week baseline period and two 3-week treatment periods separated by a 2-week washout. Patients received either amantadine 100 mg bid or matching placebo capsules. Fatigue, the effect of fatigue on an individually pre-selected activity and its effect on activities of daily living, were evaluated. Amantadine produced a small but statistically significant decrease in fatigue. An important placebo effect was noted. Mean fatigue during the washout period was lower than during the placebo run-in period, independently of which treatment had been given first. Side effects were numerous both on amantadine and on placebo. Only insomnia was significantly more common with amantadine.

Idioma original	English
Páginas (desde-hasta)	273-278
Número de páginas	6
Publicación	Canadian Journal of Neurological Sciences
Volumen	14
N.º	3
DOI	https://doi.org/10.1017/S0317167100026603
Estado	Published - ago. 1987
Publicado de forma externa	Sí

ASJC Scopus Subject Areas

Neurology
Clinical Neurology

Acceder al documento

10.1017/S0317167100026603

Otros archivos y enlaces

Citar esto

Hader, W., Duquette, P., Winnipeg, A. A., Hashimoto, S., Noseworthy, J., Sawa, G., Brunet, D., Nelson, R., Gray, T., Klein, G., Francis, G., Lapierre, Y., Weinshenker, B., Barkas, W., Philips, S., Girard, M., & Murray, T. J. (1987). A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis. Canadian Journal of Neurological Sciences, 14(3), 273-278. https://doi.org/10.1017/S0317167100026603

Hader, W, Duquette, P, Winnipeg, AA, Hashimoto, S, Noseworthy, J, Sawa, G, Brunet, D, Nelson, R, Gray, T, Klein, G, Francis, G, Lapierre, Y, Weinshenker, B, Barkas, W, Philips, S, Girard, M & Murray, TJ 1987, 'A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis', Canadian Journal of Neurological Sciences, vol. 14, n.º 3, pp. 273-278. https://doi.org/10.1017/S0317167100026603

@article{8a829ff28fb3447d943dbcf389bda7ad,

title = "A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis",

abstract = "One hundred and fifteen patients with definite multiple sclerosis (M.S.) and chronic persistent fatigue were studied. This ten-week cross-over study consisted of a 2-week baseline period and two 3-week treatment periods separated by a 2-week washout. Patients received either amantadine 100 mg bid or matching placebo capsules. Fatigue, the effect of fatigue on an individually pre-selected activity and its effect on activities of daily living, were evaluated. Amantadine produced a small but statistically significant decrease in fatigue. An important placebo effect was noted. Mean fatigue during the washout period was lower than during the placebo run-in period, independently of which treatment had been given first. Side effects were numerous both on amantadine and on placebo. Only insomnia was significantly more common with amantadine.",

author = "W. Hader and P. Duquette and Winnipeg, {A. Auty} and S. Hashimoto and J. Noseworthy and G. Sawa and D. Brunet and R. Nelson and T. Gray and G. Klein and G. Francis and Y. Lapierre and B. Weinshenker and W. Barkas and S. Philips and M. Girard and Murray, {T. J.}",

year = "1987",

month = aug,

doi = "10.1017/S0317167100026603",

language = "English",

volume = "14",

pages = "273--278",

journal = "Canadian Journal of Neurological Sciences",

issn = "0317-1671",

publisher = "Canadian Journal of Neurological Sciences",

number = "3",

}

TY - JOUR

T1 - A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis

AU - Hader, W.

AU - Duquette, P.

AU - Winnipeg, A. Auty

AU - Hashimoto, S.

AU - Noseworthy, J.

AU - Sawa, G.

AU - Brunet, D.

AU - Nelson, R.

AU - Gray, T.

AU - Klein, G.

AU - Francis, G.

AU - Lapierre, Y.

AU - Weinshenker, B.

AU - Barkas, W.

AU - Philips, S.

AU - Girard, M.

AU - Murray, T. J.

PY - 1987/8

Y1 - 1987/8

N2 - One hundred and fifteen patients with definite multiple sclerosis (M.S.) and chronic persistent fatigue were studied. This ten-week cross-over study consisted of a 2-week baseline period and two 3-week treatment periods separated by a 2-week washout. Patients received either amantadine 100 mg bid or matching placebo capsules. Fatigue, the effect of fatigue on an individually pre-selected activity and its effect on activities of daily living, were evaluated. Amantadine produced a small but statistically significant decrease in fatigue. An important placebo effect was noted. Mean fatigue during the washout period was lower than during the placebo run-in period, independently of which treatment had been given first. Side effects were numerous both on amantadine and on placebo. Only insomnia was significantly more common with amantadine.

AB - One hundred and fifteen patients with definite multiple sclerosis (M.S.) and chronic persistent fatigue were studied. This ten-week cross-over study consisted of a 2-week baseline period and two 3-week treatment periods separated by a 2-week washout. Patients received either amantadine 100 mg bid or matching placebo capsules. Fatigue, the effect of fatigue on an individually pre-selected activity and its effect on activities of daily living, were evaluated. Amantadine produced a small but statistically significant decrease in fatigue. An important placebo effect was noted. Mean fatigue during the washout period was lower than during the placebo run-in period, independently of which treatment had been given first. Side effects were numerous both on amantadine and on placebo. Only insomnia was significantly more common with amantadine.

UR - http://www.scopus.com/inward/record.url?scp=0023231728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023231728&partnerID=8YFLogxK

U2 - 10.1017/S0317167100026603

DO - 10.1017/S0317167100026603

M3 - Article

C2 - 2889518

AN - SCOPUS:0023231728

SN - 0317-1671

VL - 14

SP - 273

EP - 278

JO - Canadian Journal of Neurological Sciences

JF - Canadian Journal of Neurological Sciences

IS - 3

ER -

A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis

Resumen

ASJC Scopus Subject Areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto